KR20050047693A - Flavonoid-deposited polymer composite particles and a process for preparation of the same, and cosmetic compositions containing the same - Google Patents
Flavonoid-deposited polymer composite particles and a process for preparation of the same, and cosmetic compositions containing the same Download PDFInfo
- Publication number
- KR20050047693A KR20050047693A KR1020030081451A KR20030081451A KR20050047693A KR 20050047693 A KR20050047693 A KR 20050047693A KR 1020030081451 A KR1020030081451 A KR 1020030081451A KR 20030081451 A KR20030081451 A KR 20030081451A KR 20050047693 A KR20050047693 A KR 20050047693A
- Authority
- KR
- South Korea
- Prior art keywords
- polymer composite
- flavonoid
- flavonoids
- egcg
- meth
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 98
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000002537 cosmetic Substances 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 5
- 230000008569 process Effects 0.000 title description 3
- 239000011246 composite particle Substances 0.000 title 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 81
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 78
- 229940030275 epigallocatechin gallate Drugs 0.000 claims abstract description 77
- 239000002245 particle Substances 0.000 claims abstract description 72
- 229930003935 flavonoid Natural products 0.000 claims abstract description 60
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 60
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 60
- 238000009472 formulation Methods 0.000 claims abstract description 57
- 239000002131 composite material Substances 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 238000000151 deposition Methods 0.000 claims description 21
- -1 allyl compound Chemical class 0.000 claims description 19
- 239000000178 monomer Substances 0.000 claims description 15
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 239000003999 initiator Substances 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 7
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004971 Cross linker Substances 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 4
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
- 150000002978 peroxides Chemical class 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004641 Diallyl-phthalate Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 150000003926 acrylamides Chemical class 0.000 claims description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 3
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 150000001805 chlorine compounds Chemical class 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 3
- 235000012734 epicatechin Nutrition 0.000 claims description 3
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 3
- UHESRSKEBRADOO-UHFFFAOYSA-N ethyl carbamate;prop-2-enoic acid Chemical class OC(=O)C=C.CCOC(N)=O UHESRSKEBRADOO-UHFFFAOYSA-N 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 230000000379 polymerizing effect Effects 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 229930013783 (-)-epicatechin Natural products 0.000 claims description 2
- 235000007355 (-)-epicatechin Nutrition 0.000 claims description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 2
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 claims description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 2
- GYQDOAKHUGURPD-UHFFFAOYSA-N 5,7-Dihydroxy-2-(4-hydroxyphenyl)-1-benzopyrylium chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C1=CC=C(C(O)=CC(O)=C2)C2=[O+]1 GYQDOAKHUGURPD-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 230000001804 emulsifying effect Effects 0.000 claims description 2
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940045109 genistein Drugs 0.000 claims description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 2
- 235000006539 genistein Nutrition 0.000 claims description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 2
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001587 hesperetin Drugs 0.000 claims description 2
- 235000010209 hesperetin Nutrition 0.000 claims description 2
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- KCTAWXVAICEBSD-UHFFFAOYSA-N prop-2-enoyloxy prop-2-eneperoxoate Chemical compound C=CC(=O)OOOC(=O)C=C KCTAWXVAICEBSD-UHFFFAOYSA-N 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 9
- 239000001301 oxygen Substances 0.000 abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 abstract description 9
- 238000004925 denaturation Methods 0.000 abstract description 7
- 230000036425 denaturation Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001766 physiological effect Effects 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 5
- 230000008021 deposition Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 238000003860 storage Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 125000002560 nitrile group Chemical group 0.000 description 5
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 4
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000010557 suspension polymerization reaction Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 3
- 235000005487 catechin Nutrition 0.000 description 3
- 238000005137 deposition process Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 229940117958 vinyl acetate Drugs 0.000 description 3
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- WYGWHHGCAGTUCH-UHFFFAOYSA-N 2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile Chemical compound CC(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)C WYGWHHGCAGTUCH-UHFFFAOYSA-N 0.000 description 2
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- 229940059574 pentaerithrityl Drugs 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JMYZLRSSLFFUQN-UHFFFAOYSA-N (2-chlorobenzoyl) 2-chlorobenzenecarboperoxoate Chemical compound ClC1=CC=CC=C1C(=O)OOC(=O)C1=CC=CC=C1Cl JMYZLRSSLFFUQN-UHFFFAOYSA-N 0.000 description 1
- WOTCBNVQQFUGLX-UHFFFAOYSA-N (2-methoxybenzoyl) 2-methoxybenzenecarboperoxoate Chemical compound COC1=CC=CC=C1C(=O)OOC(=O)C1=CC=CC=C1OC WOTCBNVQQFUGLX-UHFFFAOYSA-N 0.000 description 1
- FVQMJJQUGGVLEP-UHFFFAOYSA-N (2-methylpropan-2-yl)oxy 2-ethylhexaneperoxoate Chemical compound CCCCC(CC)C(=O)OOOC(C)(C)C FVQMJJQUGGVLEP-UHFFFAOYSA-N 0.000 description 1
- MWZJGRDWJVHRDV-UHFFFAOYSA-N 1,4-bis(ethenoxy)butane Chemical compound C=COCCCCOC=C MWZJGRDWJVHRDV-UHFFFAOYSA-N 0.000 description 1
- HMDQPBSDHHTRNI-UHFFFAOYSA-N 1-(chloromethyl)-3-ethenylbenzene Chemical compound ClCC1=CC=CC(C=C)=C1 HMDQPBSDHHTRNI-UHFFFAOYSA-N 0.000 description 1
- ZRZHXNCATOYMJH-UHFFFAOYSA-N 1-(chloromethyl)-4-ethenylbenzene Chemical compound ClCC1=CC=C(C=C)C=C1 ZRZHXNCATOYMJH-UHFFFAOYSA-N 0.000 description 1
- BOVQCIDBZXNFEJ-UHFFFAOYSA-N 1-chloro-3-ethenylbenzene Chemical compound ClC1=CC=CC(C=C)=C1 BOVQCIDBZXNFEJ-UHFFFAOYSA-N 0.000 description 1
- KTZVZZJJVJQZHV-UHFFFAOYSA-N 1-chloro-4-ethenylbenzene Chemical compound ClC1=CC=C(C=C)C=C1 KTZVZZJJVJQZHV-UHFFFAOYSA-N 0.000 description 1
- LGJCFVYMIJLQJO-UHFFFAOYSA-N 1-dodecylperoxydodecane Chemical compound CCCCCCCCCCCCOOCCCCCCCCCCCC LGJCFVYMIJLQJO-UHFFFAOYSA-N 0.000 description 1
- XHUZSRRCICJJCN-UHFFFAOYSA-N 1-ethenyl-3-ethylbenzene Chemical compound CCC1=CC=CC(C=C)=C1 XHUZSRRCICJJCN-UHFFFAOYSA-N 0.000 description 1
- JZHGRUMIRATHIU-UHFFFAOYSA-N 1-ethenyl-3-methylbenzene Chemical compound CC1=CC=CC(C=C)=C1 JZHGRUMIRATHIU-UHFFFAOYSA-N 0.000 description 1
- WHFHDVDXYKOSKI-UHFFFAOYSA-N 1-ethenyl-4-ethylbenzene Chemical compound CCC1=CC=C(C=C)C=C1 WHFHDVDXYKOSKI-UHFFFAOYSA-N 0.000 description 1
- CDNNKGWZSNSADW-UHFFFAOYSA-N 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20-icosamethyl-1,3,5,7,9,11,13,15,17,19-decaoxa-2,4,6,8,10,12,14,16,18,20-decasilacycloicosane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 CDNNKGWZSNSADW-UHFFFAOYSA-N 0.000 description 1
- DPGYCJUCJYUHTM-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-yloxy 2-ethylhexaneperoxoate Chemical compound CCCCC(CC)C(=O)OOOC(C)(C)CC(C)(C)C DPGYCJUCJYUHTM-UHFFFAOYSA-N 0.000 description 1
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- WOYWLLHHWAMFCB-UHFFFAOYSA-N 2-ethylhexyl acetate Chemical compound CCCCC(CC)COC(C)=O WOYWLLHHWAMFCB-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RCEJCSULJQNRQQ-UHFFFAOYSA-N 2-methylbutanenitrile Chemical compound CCC(C)C#N RCEJCSULJQNRQQ-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- CAMBAGZYTIDFBK-UHFFFAOYSA-N 3-tert-butylperoxy-2-methylpropan-1-ol Chemical compound CC(CO)COOC(C)(C)C CAMBAGZYTIDFBK-UHFFFAOYSA-N 0.000 description 1
- JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- XJOBOFWTZOKMOH-UHFFFAOYSA-N decanoyl decaneperoxoate Chemical compound CCCCCCCCCC(=O)OOC(=O)CCCCCCCCC XJOBOFWTZOKMOH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- SRSFOMHQIATOFV-UHFFFAOYSA-N octanoyl octaneperoxoate Chemical compound CCCCCCCC(=O)OOC(=O)CCCCCCC SRSFOMHQIATOFV-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010558 suspension polymerization method Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GRPURDFRFHUDSP-UHFFFAOYSA-N tris(prop-2-enyl) benzene-1,2,4-tricarboxylate Chemical compound C=CCOC(=O)C1=CC=C(C(=O)OCC=C)C(C(=O)OCC=C)=C1 GRPURDFRFHUDSP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/22—After-treatment of expandable particles; Forming foamed products
- C08J9/224—Surface treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0279—Porous; Hollow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/612—By organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 플라보노이드/고분자 복합구형체 및 이의 제조방법, 및 이를 함유하는 화장료 조성물에 관한 것으로, 본 발명의 플라보노이드/고분자 복합구형체는 에피갈로카테킨갈레이트(EGCg) 등의 플라보노이드를 다공성 고분자 입자의 넓은 표면적에 침착, 고정시킨 것으로, 산소나 빛 등의 외부 자극에 의한 플라보노이드의 분자 변성을 최소화함으로써 다양한 화장료 제형에의 적용이 기대되며, 특히 0.01~1000㎛의 입자크기 범위로서 평균 5~10㎛의 입자크기를갖는 구형체이기 때문에 화장료 제형에 적용시 펴발림성 등의 사용감이 우수하여 플라보노이드의 생리활성 효과를 화장료 제형으로 제공할 수 있다.The present invention relates to a flavonoid / polymer composite sphere and a method for producing the same, and a cosmetic composition containing the same, the flavonoid / polymer composite sphere of the present invention is a flavonoid such as epigallocatechin gallate (EGCg) porous polymer particles It is deposited and fixed on a large surface area, and it is expected to be applied to various cosmetic formulations by minimizing the molecular denaturation of flavonoids by external stimulation such as oxygen or light. Especially, the particle size range of 0.01 ~ 1000㎛ is 5-10 on average. Since it is a spherical body having a particle size of μm, when applied to a cosmetic formulation, it is excellent in feeling such as spreadability and can provide the physiological activity effect of flavonoids in the cosmetic formulation.
Description
본 발명은 플라보노이드/고분자 복합구형체 및 이의 제조방법, 및 이를 함유하는 화장료 조성물에 관한 것으로, 본 발명의 플라보노이드/고분자 복합구형체는 에피갈로카테킨갈레이트(EGCg) 등의 플라보노이드를 다공성 고분자 입자의 넓은 표면적에 침착, 고정시킨 것으로, 산소나 빛 등의 외부 자극에 의한 플라보노이드의 분자 변성을 최소화함으로써 다양한 화장료 제형에의 적용이 기대되며, 특히, 0.01~1000㎛의 입자크기 범위로서 평균 5~10㎛의 입자크기를갖는 구형체이기 때문에 화장료 제형에 적용시 펴발림성 등의 사용감이 우수하여 플라보노이드의 생리활성 효과를 화장료 제형으로 제공할 수 있다.The present invention relates to a flavonoid / polymer composite sphere and a method for producing the same, and a cosmetic composition containing the same, the flavonoid / polymer composite sphere of the present invention is a flavonoid such as epigallocatechin gallate (EGCg) porous polymer particles As it is deposited and fixed on a large surface area of, it is expected to be applied to various cosmetic formulations by minimizing molecular denaturation of flavonoids by external stimulation such as oxygen or light, and in particular, the average particle size ranges from 0.01 to 1000 μm. Since it is a spherical body having a particle size of 10㎛, when applied to the cosmetic formulations, it is excellent in feeling such as spreadability and can provide the physiological activity effect of flavonoids in cosmetic formulations.
녹차의 우수한 효능은 녹차에 풍부하게 존재하고 있는 플라보노이드류에 의한 것으로, 특히 카테킨(catechin)에 의한 것으로 알려져 있다. 이중 에피카테킨[(-)EC], 에피갈로카테킨[(-)EGC], 에피카테킨갈레이트[(-)ECg], 에피갈로카테킨갈레이트[(-)EGCg] 등은 '차 카테킨'으로 지칭된다. 그 중에서도 하기의 화학식 1의 분자 구조를 갖는 에피갈로카테킨갈레이트(이하, "EGCg")가 차 카테킨류 중에서도 구성 비율이 가장 높고, 각종 생리활성 효과도 뛰어난 것으로 알려져 있다.The excellent efficacy of green tea is due to the flavonoids present in abundance in green tea, and is particularly known to be due to catechin. Epicatechin [(-) EC], epigallocatechin [(-) EGC], epicatechin gallate [(-) ECg], epigallocatechin gallate [(-) EGCg], etc. are referred to as 'tea catechin' do. Among them, epigallocatechin gallate (hereinafter referred to as "EGCg") having a molecular structure of the formula (1) is known to have the highest composition ratio among tea catechins and excellent in various physiological activity effects.
최근, 녹차의 인체에 대한 효능은 세계적으로 주목받고 있고, 세계 각국에서 생체 효능에 대한 연구가 활발히 진행되고 있다. 녹차 카테킨 중 특히, EGCg는 항산화 효과, 항암 효과 {(1) Jovanovic, S. V. et al,(1994) Flavonoids as antioxidants. J. Am. Chem. Soc.116, 4846-4851. (2) Salah, N. et al,(1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys. 322, 339-346. (3)Dreosti, I. E. (1996) Bioactive ingredients: Antioxidants and polyphenols in tea. Nutr. Rev.54, 51-58.(4) Yang, C. S. et al, (1993) Tea and cancer. J. Natl.Cancer Inst.85, 1038-1049.}, 콜레스테롤 저하 효과가 있는 것으로 알려져 있다. 또한 피부에 도포 시 생체 내에서 활성 산소에 의한 산화작용을 억제하고 과산화물의 생성을 억제함으로써 생체막의 노화를 방지하고 콜라겐의 생합성을 촉진함으로써 피부의 탄력 상승 및 피부노화의 예방, 개선의 효과가 있으며, 뿐만 아니라 피부에 대한 자극이 없어 유효한 생리활성 물질로 주목받고 있다.Recently, the efficacy of green tea on the human body has been attracting attention from around the world, and research on bioefficacy has been actively conducted in various countries around the world. In particular among the green tea catechins, EGCg has antioxidant and anticancer effects {(1) Jovanovic, SV et al , (1994) Flavonoids as antioxidants. J. Am. Chem. Soc . 116, 4846-4851. (2) Salah, N. et al , (1995) Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys . 322, 339-346. (3) Dreosti, IE (1996) Bioactive ingredients: Antioxidants and polyphenols in tea. Nutr. Rev. 54, 51-58. (4) Yang, CS et al , (1993) Tea and cancer. J. Natl. Cancer Inst. 85, 1038-1049.}, Is known to have a cholesterol-lowering effect. In addition, when applied to the skin, it inhibits the oxidative action by active oxygen in the living body and inhibits the formation of peroxides, thereby preventing the aging of the biofilm and promoting the biosynthesis of collagen, thereby increasing the elasticity of the skin and preventing and improving skin aging. In addition, it is attracting attention as an effective bioactive substance because it has no skin irritation.
그러나, EGCg는 화장료 기제로 사용되는 물 또는 오일에 대한 용해도가 낮아 침상의 결정형태 그대로 분산 배합되기 때문에 거친 입자감을 많이 나타내어, 우수한 생리활성 효과에도 불구하고, 화장품으로의 응용에 제한적이다. 또한, 수분, 산소, 빛 등의 외부 자극에 대하여 불안정하여 급속하게 분자 변성이 발생하기 때문에, 제형내에서의 역가 보존이 어려운 문제점도 있다.However, since EGCg has a low solubility in water or oil used as a cosmetic base and is dispersed and blended in the form of acicular crystals, EGCg shows a lot of coarse grains, and despite its excellent physiological activity effect, it is limited to application to cosmetics. In addition, since molecular degeneration occurs rapidly due to instability to external stimuli such as moisture, oxygen, light, etc., there is also a problem that it is difficult to preserve the titer in the formulation.
따라서, EGCg의 거친 사용감을 개선하고, 외부 자극에 의한 분자 변성을 최소화할 수 있는 새로운 안정화 시스템의 개발이 절실히 요구되고 있다.Therefore, there is an urgent need to develop a new stabilization system that can improve the rough feeling of EGCg and minimize molecular denaturation by external stimuli.
이에, 본 발명자들은 화장료 제형에 적용시 EGCg의 거친 사용감을 개선하고 외부 자극에 대한 EGCg의 안정화 방법를 연구하던 중, 다량의 EGCg를 다공성 고분자 입자의 넓은 표면적에 침착, 고정시킴으로써 얻어지는 복합구형체의 형태로 제형화하는 경우, 피부 도포시 펴발림성이 향상되고 거친 입자감이 없어 사용감이 개선되며, 뿐만 아니라 산소나 빛 등의 외부 자극에 의한 분자 변성이 최소화되어 제형내 역가 보존이 가능함을 발견하고 본 발명을 완성하게 되었다.Therefore, the inventors of the present invention, while studying the method of stabilizing the EGCg against external stimuli and improve the rough feeling of EGCg when applied to the cosmetic formulation, the form of a composite sphere obtained by depositing and fixing a large amount of EGCg on the large surface area of the porous polymer particles When formulated as, the spreadability is improved when the skin is applied and there is no coarse grain feeling, the usability is improved, as well as the molecular denaturation caused by external stimulation such as oxygen or light is minimized, and thus the titer can be preserved in the formulation. To complete.
따라서, 본 발명의 첫번째 목적은 EGCg를 포함한 플라보노이드의 외부 자극에 대한 안정화 시스템을 제공하는 것이다.Accordingly, a first object of the present invention is to provide a stabilization system for external stimulation of flavonoids containing EGCg.
본 발명의 두번째 목적은 EGCg를 포함한 플라보노이드를 화장료 제형에 적용시 이들의 사용감을 개선하는 방법을 제공하는 것이다. It is a second object of the present invention to provide a method for improving their feeling when applying flavonoids containing EGCg to cosmetic formulations.
또한, 본 발명의 세번째 목적은 다공성 고분자 입자 표면에 EGCg를 포함한 플라보노이드를 균일하게 침착, 고정시킴으로써 얻어지는 플라보노이드/고분자 복합구형체를 제공하는 것이다.It is also a third object of the present invention to provide a flavonoid / polymer composite sphere obtained by uniformly depositing and fixing flavonoids containing EGCg on the surface of porous polymer particles.
본 발명의 네번째 목적은 상기한 플라보노이드/고분자 복합구형체의 제조방법을 제공하는 것이다.It is a fourth object of the present invention to provide a method for producing the flavonoid / polymer composite sphere.
본 발명의 다섯번째 목적은 상기한 플라보노이드/고분자 복합구형체를 유효성분으로 함유하는 화장료 조성물을 제공하는 것이다.A fifth object of the present invention is to provide a cosmetic composition containing the above-described flavonoids / polymer composite spheres as an active ingredient.
상기한 본 발명의 첫번째 및 두번째 목적들은 상기한 세번째 목적에 의해 달성될 수 있으며, 본 발명은 상기한 목적들을 달성하기 위하여 EGCg 등의 플라보노이드(이하, "EGCg"로 대표한다)를 다공성 고분자 입자의 넓은 표면적에 침착, 고정시킴을 특징으로 한다.The first and second objects of the present invention can be achieved by the third object described above, and the present invention provides a flavonoid such as EGCg (hereinafter referred to as "EGCg") of porous polymer particles in order to achieve the above objects. It is characterized by being deposited and fixed on a large surface area.
본 발명에 의하면 다공성 고분자 입자의 표면에 다량의 EGCg가 분자 단위로 고정된 EGCg/고분자 복합구형체가 제공되며, 본 발명의 복합구형체는 미세 분말상으로 5~10㎛의 평균 입자크기를 갖는 구형체이기 때문에 다양한 화장료 제형에 배합이 용이하고, 뿐만 아니라 산소나 빛 등의 외부 자극에 의한 플라보노이드의 분자 변성이 최소화되어 제형내에서 역가 보존이 가능하며, 피부 도포시 펴발림성 등의 사용감이 우수하여 플라보노이드의 생리활성 효과를 화장료 제형으로 제공할 수 있다.According to the present invention, there is provided an EGCg / polymer composite sphere in which a large amount of EGCg is fixed in molecular units on the surface of the porous polymer particles, and the composite sphere of the present invention has a fine powder having a mean particle size of 5 to 10 μm. Because of this, it is easy to mix in various cosmetic formulations, and also the molecular degeneration of flavonoids by external stimulation such as oxygen or light is minimized to preserve the titer in the formulation, and the flavonoids have excellent feeling of spreadability when applying skin. The bioactive effect of can be provided in the cosmetic formulation.
이하, 본 발명을 더욱 구체적으로 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 플라보노이드/고분자 복합구형체는, 현탁 중합에 의해 제조된 다공성 입자의 넓은 표면적에 플라보노이드를 침착, 고정시킨 것으로, 제조 방법은 다음의 단계를 포함한다 :The flavonoid / polymer composite spherical body of the present invention is obtained by depositing and fixing flavonoids on a large surface area of porous particles prepared by suspension polymerization. The manufacturing method includes the following steps:
(1) 단량체, 가교제 및 개시제를 용매에 용해시키는 단계;(1) dissolving monomers, crosslinkers and initiators in a solvent;
(2) 분산 안정화제 존재 하에 상기 단량체 용액을 유화시켜 에멀젼을 수득하는 단계;(2) emulsifying the monomer solution in the presence of a dispersion stabilizer to obtain an emulsion;
(3) 상기 에멀젼을 중합시킨 후, 용매를 제거하고 다공성 고분자 입자를 회수하는 단계; 및(3) after polymerizing the emulsion, removing the solvent and recovering the porous polymer particles; And
(4) 회수된 다공성 고분자 입자에 플라보노이드를 침착시키는 단계.(4) depositing flavonoids on the recovered porous polymer particles.
본 발명에서 표면적이 넓은 다공성 고분자 입자는 현탁 중합을 이용하여 제조한다. 단량체/가교제/개시제를 용매에 용해시킨 후 적당한 분산안정제의 존재 하에 호모게나이저를 이용하여 유화시켜 에멀젼을 수득한 후에 교반하면서 중합온도를 유지하면 현탁 중합이 진행된다.In the present invention, the porous polymer particles having a large surface area are prepared by using suspension polymerization. The monomer / crosslinker / initiator is dissolved in a solvent and then emulsified using a homogenizer in the presence of a suitable dispersion stabilizer to obtain an emulsion, followed by suspension polymerization when the polymerization temperature is maintained while stirring.
다공성 구조는 현탁 중합 동안 고분자 가교망의 상분리를 유도함으로써 얻을 수 있다. 단량체, 가교제, 개시제, 용매를 포함한 액적 내에서 중합반응이 진행되면, 성장하는 고분자 가교망이 용매에 대해 용해력을 잃게 되면서 수 나노 크기의 미세 구형으로 응집체를 형성하게 된다. 이 미세 구형체는 액적 내에서 형성되어 경질특성이 강하기 때문에 응집체 사이를 용매가 채우고 있다. 따라서, 용매만 선택적으로 제거하면 표면적이 극대화된 다공성을 갖는 고분자 입자를 얻을 수 있다.The porous structure can be obtained by inducing phase separation of the polymer crosslinked network during suspension polymerization. As the polymerization proceeds in droplets including monomers, crosslinkers, initiators, and solvents, the growing polymer crosslinking network loses its solubility in solvents and forms aggregates into microspheres of several nanoscales. Since these fine spherical bodies are formed in the droplets and the hard properties are strong, the solvent fills the aggregates. Therefore, if only the solvent is selectively removed, it is possible to obtain a polymer particle having a porosity with a maximum surface area.
이때, 히드록시기, 아민기, 니트릴기 등을 갖는 단량체를 공중합시키면 표면에 플라보노이드의 침착을 유도할 수 있는 상호작용기를 지닌 다공성 고분자 입자를 제조할 수 있다. 입자 표면에 이러한 상호작용기가 존재할 경우 수상에서 플라보노이드와 강한 수소결합을 유도할 수 있어 플라보노이드의 표면 침착을 더욱 강화시킬 수 있고, 침착량을 증가시킬 수 있다.In this case, copolymerizing a monomer having a hydroxyl group, an amine group, a nitrile group, or the like may produce a porous polymer particle having an interaction group capable of inducing the deposition of flavonoids on the surface. The presence of such interacting groups on the particle surface can induce strong hydrogen bonding with flavonoids in the water phase, which can further enhance the surface deposition of the flavonoids and increase the amount of deposition.
플라보노이드의 침착은 수상에서 진행되며, 구체적으로 다공성 고분자 입자를 물에 분산시킨 후에 플라보노이드 수용액을 첨가하여 침착시키고, 그런 다음 여과 및 건조 공정을 적용시키면 플라보노이드가 표면 침착된 다공성 고분자 복합구형체를 수득할 수 있다. 이렇게 되면 플라보노이드가 분자 단위로 다공성 고분자의 표면에 침착됨으로써 고분자 표면에 고정될 수 있고, 다양한 화장료 조성물에 사용할 수 있게 된다. Deposition of flavonoids is carried out in the water phase, specifically, the porous polymer particles are dispersed in water, followed by deposition by addition of an aqueous solution of flavonoids, and then the filtration and drying process is applied to obtain a porous polymer composite sphere in which flavonoids are surface deposited. Can be. In this case, the flavonoids may be fixed on the surface of the polymer by being deposited on the surface of the porous polymer in molecular units, and may be used in various cosmetic compositions.
상기한 다공성 고분자 입자에 침착되는 플라보노이드는 헤스페레틴(hesperetin), 제니스테인(genistein), 아피제니딘(apigenidin), 에피카테킨[(-)epicatechin], 에피갈로카테킨[(-)epigallocatechin], 에피카테킨갈레이트[(-)epicatechingallate], 에피갈로카테킨갈레이트[(-)epigallocatechingallate] 및 레스베라트롤(resveratrol)로 이루어진 군에서 선택된 1종 이상을 사용할 수 있다. 본 명세서에서는 에피갈로카테킨갈레이트(EGCg)를 상기한 플라보노이드를 대표하여 기재한다. 플라보노이드의 표면 침착량은 총 고분자 중량 대비 0.01~90중량%이다.Flavonoids deposited on the porous polymer particles are hesperetin, genistein, apigenidin, epicatechin [(-) epicatechin, epigallocatechin [(-) epigallocatechin], epicatechingal At least one selected from the group consisting of late [(-) epicatechingallate], epigallocatechin gallate [(-) epigallocatechingallate] and resveratrol can be used. Epigallocatechin gallate (EGCg) is described herein as representative of the flavonoids described above. The surface deposition amount of flavonoids is 0.01 to 90% by weight relative to the total polymer weight.
상기한 단계(1)에서 다공성 구조를 갖는 고분자 입자를 제조하는데 사용할 수 있는 단량체는 라디칼 중합이 가능한 것이라면 그 종류가 특별히 한정되지 않는다. 또한, 단량체와 가교제를 혼합하여 공중합체 형태의 다공성 고분자 입자를 제조할 수도 있고, 가교제만을 이용하여 다공성 고분자 입자를 제조할 수도 있다. 단량체로는, 스티렌; 아크릴레이트; 비닐 아세테이트; 비닐 에테르; 말레산을 포함하는 불포화 카르복시산; 알킬(메타) 아크릴아미드; (메타)아크릴로니트릴 및 이들의 유도체로 이루어진 군에서 선택할 수 있다. 구체적으로는 스티렌, p- 또는 m-메틸스티렌, p- 또는 m-에틸스티렌, p- 또는 m-클로로스티렌, p- 또는 m -클로로메틸스티렌, 스티렌설폰산, p- 또는 m-t-부톡시스티렌, 메틸 (메타)아크릴레이트, 에틸 (메타)아크릴레이트, 프로필 (메타)아크릴레이트, n-부틸 (메타)아크릴레이트, 이소부틸 (메타)아크릴레이트, t-부틸 (메타)아크릴레이트, 2-에틸헥실 (메타)아크릴레이트, n-옥틸 (메타)아크릴레이트, 라우릴 (메타)아크릴레이트, 스테아릴 (메타)아크릴레이트, 2-히드록시에틸 (메타)아크릴레이트, 폴리에틸렌 글리콜 (메타)아크릴레이트, 메톡시폴리에틸렌 글리콜 (메타)아크릴레이트, 글리시딜 (메타)아크릴레이트, 디메틸아미노에틸 (메타)아크릴레이트, 디에틸아미노에틸 (메타)아크릴레이트, 비닐 아세테이트, 비닐 프로피오네이트, 비닐 부티레이트, 비닐 에테르, 알릴 부틸 에테르, 알릴 글리시딜 에테르, (메타)아크릴산, 말레산을 포함하는 불포화 카르복시산, 알킬(메타) 아크릴아미드, (메타)아크릴로니트릴 등을 사용할 수 있다.The monomer that can be used to prepare the polymer particles having a porous structure in the above step (1) is not particularly limited as long as it is capable of radical polymerization. In addition, the monomer and the crosslinking agent may be mixed to prepare the porous polymer particles in the form of a copolymer, or the porous polymer particles may be prepared using only the crosslinking agent. As a monomer, Styrene; Acrylates; Vinyl acetate; Vinyl ethers; Unsaturated carboxylic acids including maleic acid; Alkyl (meth) acrylamides; (Meth) acrylonitrile and derivatives thereof. Specifically, styrene, p- or m -methylstyrene, p- or m -ethylstyrene, p- or m -chlorostyrene, p- or m -chloromethylstyrene, styrenesulfonic acid, p- or m- t-part Oxystyrene, methyl (meth) acrylate, ethyl (meth) acrylate, propyl (meth) acrylate, n-butyl (meth) acrylate, isobutyl (meth) acrylate, t-butyl (meth) acrylate, 2-ethylhexyl (meth) acrylate, n-octyl (meth) acrylate, lauryl (meth) acrylate, stearyl (meth) acrylate, 2-hydroxyethyl (meth) acrylate, polyethylene glycol (meth ) Acrylate, methoxypolyethylene glycol (meth) acrylate, glycidyl (meth) acrylate, dimethylaminoethyl (meth) acrylate, diethylaminoethyl (meth) acrylate, vinyl acetate, vinyl propionate, Vinyl butyrate, non It can be used an ether, an allyl ether, allyl glycidyl ether, (meth) acrylic acid, unsaturated carboxylic acids, alkyl (meth) acrylamides containing a maleic acid, such as (meth) acrylonitrile.
또한 상기한 단계(1)에서 사용할 수 있는 가교제로는 라디칼 중합이 가능한 것으로서, 디비닐벤젠 및 디알릴프탈레이트를 포함하는 알릴 화합물; (폴리)에틸렌 글리콜 디(메타)아크릴레이트를 포함하는 (폴리)알킬렌글리콜 디(메타)아크릴레이트; 우레탄 아크릴레이트; 에폭시 아크릴레이트 및 이들의 유도체로 이루어진 군에서 선택할 수 있다. 구체적으로는, 디비닐벤젠, 1,4-디비닐옥시부탄, 디비닐술폰, 디알릴프탈레이트, 디알릴아크릴아미드, 트리알릴(이소)시아누레이트 및 트리알릴 트리멜리테이트를 포함하는 알릴 화합물; (폴리)에틸렌 글리콜 디(메타)아크릴레이트, (폴리)프로필렌 글리콜 디(메타)아크릴레이트, 펜타에릴트리톨 테트라(메타)아크릴레이트, 펜타에릴트리톨 트리(메타) 아크릴레이트, 펜타에릴트리톨 디(메타)아크릴레이트, 트리메틸올프로판 트리(메타)아크릴레이트, 디펜타에릴트리톨 헥사(메타)아크릴레이트, 디펜타에릴트리톨 펜타(메타)아크릴레이트 및 글리세롤 트리(메타)아크릴레이트를 포함하는 (폴리)알킬렌글리콜 디(메타)아크릴레이트; 우레탄 아크릴레이트; 에폭시 아크릴레이트 등을 사용할 수 있다. 상기의 가교제의 농도는 최종 고분자 입자의 다공성을 결정한다. 일반적으로는 전체 단량체 중량에 대하여 30중량% 이상이 적절하다. 이 미만의 농도에서는 상 분리가 약화되어 다공성이 약화되고 표면적이 줄어드는 경향이 있다.In addition, the cross-linking agent that can be used in the step (1) is capable of radical polymerization, allyl compounds including divinylbenzene and diallyl phthalate; (Poly) alkylene glycol di (meth) acrylate including (poly) ethylene glycol di (meth) acrylate; Urethane acrylates; Epoxy acrylates and derivatives thereof. Specifically, the allyl compound containing divinylbenzene, 1, 4- divinyloxy butane, divinyl sulfone, diallyl phthalate, diallyl acrylamide, triallyl (iso) cyanurate, and triallyl trimellitate; (Poly) ethylene glycol di (meth) acrylate, (poly) propylene glycol di (meth) acrylate, penta erythritol tetra (meth) acrylate, penta erythritol tri (meth) acrylate, penta Ryltritol di (meth) acrylate, trimethylolpropane tri (meth) acrylate, dipentaerythritol hexa (meth) acrylate, dipentaerythritol penta (meth) acrylate, and glycerol tri (meth) (Poly) alkylene glycol di (meth) acrylate including) acrylate; Urethane acrylates; Epoxy acrylate and the like can be used. The concentration of the crosslinker determines the porosity of the final polymer particles. Generally at least 30% by weight relative to the total monomer weight is appropriate. At concentrations below this, phase separation tends to be weakened, resulting in poor porosity and reduced surface area.
본 발명에 사용되는 개시제로는 유용성 개시제로서, 벤조일 퍼옥시드를 포함하는 퍼옥시드계; 2,2-아조비스이소부티로니트릴을 포함하는 아조 화합물 및 이들의 유도체로 이루어진 군에서 선택할 수 있다. 구체적으로는 벤조일 퍼옥시드, 라우릴 퍼옥시드, o-클로로벤조일 퍼옥시드, o-메톡시벤조일 퍼옥시드, t-부틸퍼옥시-2-에틸헥사노에이트, t-부틸퍼옥시이소부틸레이트, 1,1,3,3- 테트라메틸부틸퍼옥시-2-에틸헥사노에이트, 디옥타노일 퍼옥시드 및Initiators used in the present invention include oil-soluble initiators, peroxide-based containing benzoyl peroxide; It can be selected from the group consisting of azo compounds including 2,2-azobisisobutyronitrile and derivatives thereof. Specifically, benzoyl peroxide, lauryl peroxide, o -chlorobenzoyl peroxide, o -methoxybenzoyl peroxide, t-butylperoxy-2-ethylhexanoate, t-butylperoxy isobutylate, 1 , 1,3,3-tetramethylbutylperoxy-2-ethylhexanoate, dioctanoyl peroxide and
디데카노일 퍼옥시드를 포함하는 퍼옥시드계; 및 2,2-아조비스이소부티로니트릴, 2,2-아조비스(2-메틸부티로니트릴), 2,2-아조비스(2,4-디메틸발레로니트릴)을 포함하는 아조 화합물을 사용할 수 있다. 개시제의 사용량은 전체 단량체 중량에 대하여 0.1~3중량%가 바람직하다. 상기한 단계(1)에서 사용하는 용매는 선택되는 단량체와 유사한 용해도 파라미터를 지닌 것으로서, 헥산을 포함하는 선형 알칸류; 부탄올을 포함하는 탄소수 4~10의 알콜류; n-헥실 아세테이트를 포함하는 탄소수 7 이상의 알킬 에스테르; 지방족 케톤; 톨루엔을 포함하는 방향족 탄화수소; 메틸렌클로라이드를 포함하는 염소화합물 및 이들의 유도체로 이루어진 군에서 선택할 수 있다. 구체적으로는 헥산, 헵탄, 옥탄, 노난 및 데칸을 포함하는 선형 알칸류; 부탄올, 선형 또는 가지형 펜탄올, 헥산올, 헵탄올, 옥탄올, 노난올 및 데칸올을 포함하는 탄소수 4~10의 알콜류; n-헥실 아세테이트, 2-에틸헥실 아세테이트, 메틸 올레이트, 디부틸 세바케이트, 디부틸 아디페이트(adipate) 및 디부틸 카바메이트를 포함하는 탄소수 7 이상의 알킬 에스테르; 메틸이소부틸케톤 및 이소부틸케톤을 포함하는 지방족 케톤; 벤젠, 톨루엔, o- 또는 p-크실렌을 포함하는 방향족 탄화수소; 메틸렌클로라이드, 클로로포름 및 사염화탄소를 포함하는 염소화합물 등을 사용할 수 있으나, 이에 한정되는 것은 아니다. 바람직하게는 상 분리를 용이하게 하여 기공 구조를 잘 형성하게 하는 톨루엔, 케톤 등을 사용하는 것이 좋다.Peroxides, including didecanoyl peroxide; And azo compounds including 2,2-azobisisobutyronitrile, 2,2-azobis (2-methylbutyronitrile), and 2,2-azobis (2,4-dimethylvaleronitrile). Can be. As for the usage-amount of an initiator, 0.1-3 weight% is preferable with respect to the total monomer weight. The solvent used in the above step (1) has a solubility parameter similar to that of the monomer selected, and includes linear alkanes including hexane; Alcohols having 4 to 10 carbon atoms including butanol; alkyl esters having at least 7 carbon atoms including n-hexyl acetate; Aliphatic ketones; Aromatic hydrocarbons including toluene; It can be selected from the group consisting of chlorine compounds including methylene chloride and derivatives thereof. Specifically, linear alkanes including hexane, heptane, octane, nonane and decane; Alcohols having 4 to 10 carbon atoms including butanol, linear or branched pentanol, hexanol, heptanol, octanol, nonanol and decanol; alkyl esters having at least 7 carbon atoms including n-hexyl acetate, 2-ethylhexyl acetate, methyl oleate, dibutyl sebacate, dibutyl adipate and dibutyl carbamate; Aliphatic ketones including methyl isobutyl ketone and isobutyl ketone; Aromatic hydrocarbons including benzene, toluene, o- or p -xylene; Chlorine compounds including methylene chloride, chloroform and carbon tetrachloride may be used, but is not limited thereto. It is preferable to use toluene, ketone, or the like, which facilitates phase separation to form a pore structure well.
상기한 단계(2)에서 사용하는 분산 안정화제는 수상에 녹을 수 있는 고분자로서, 구체적으로는 젤라틴, 스타치, 히드록시에틸셀룰로오즈, 카르복시메틸셀룰로오즈, 폴리비닐피롤리돈, 폴리비닐 알킬 에테르, 폴리비닐알콜, 폴리디메틸실록산/폴리스티렌 블록공중합체 등을 사용할 수 있다. 사용량은 에멀젼화 과정에서 생성된 고분자 입자가 중력에 의한 침적이나 입자간 응집을 억제할 수 있을 정도로 사용하는 것이 좋은데, 전체 반응물에 대하여 0.1~30 중량%의 범위로 사용하는 것이 바람직하다. 이는 0.1중량% 미만의 농도에서는 계면 침착에 의한 분산 안정성이 급격히 저하되고, 30중량%를 초과하는 경우에는 계의 점도가 급증하여 공정이 불가능해지기 때문이다.The dispersion stabilizer used in the above step (2) is a polymer that can be dissolved in an aqueous phase, specifically gelatin, starch, hydroxyethyl cellulose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alkyl ether, poly Vinyl alcohol, polydimethylsiloxane / polystyrene block copolymer, and the like. The amount of the polymer particles used in the emulsification process is preferably used to the extent that the polymer particles produced during the emulsification can suppress the deposition due to gravity and the aggregation between the particles, but is preferably used in the range of 0.1 to 30% by weight based on the total reactants. This is because, at a concentration of less than 0.1% by weight, the dispersion stability due to interfacial deposition is sharply lowered, and when it exceeds 30% by weight, the viscosity of the system increases rapidly, making the process impossible.
이렇게 하여 제조되는 다공성 고분자 입자는 0.01~1,000㎛, 평균적으로 5~10㎛의 입자크기를 가진 구형체로서, 10㎡/g 이상의 넓은 표면적과 10~20㎚ 크기의 작은 포어들을 갖고 있어 플라보노이드의 침착이 용이하다.The porous polymer particles thus prepared are spherical bodies having a particle size of 0.01 to 1,000 μm, on average 5 to 10 μm, and have a large surface area of 10 m 2 / g or more and small pores of 10 to 20 nm in size to deposit flavonoids. This is easy.
상기한 단계(4)에서 플라보노이드의 침착은 수상에서 이루어지는데, 구체적으로는 pH 2~7의 물에 다공성 고분자 입자를 분산시킨 후, 플라보노이드를 도입하여 다공성 고분자 입자 표면에 존재하는 상호작용기와 플라보노이드 분자 내에 존재하는 히드록시기의 복합화를 유도한다. pH2 미만일 경우에는 과량의 수소이온에 의해 수소결합이 방해 받을 수 있고, pH7를 초과할 경우에는 과량의 수산화 이온에 의해 수소결합이 방해 받을 수 있다.In the step (4), the deposition of flavonoids is carried out in an aqueous phase. Specifically, after dispersing the porous polymer particles in water at pH 2-7, the flavonoids are introduced to introduce the interaction groups and flavonoid molecules present on the surface of the porous polymer particles. Induces the complexation of the hydroxyl groups present within. When the pH is less than 2, hydrogen bonding may be interrupted by an excess of hydrogen ions, and when the pH is above 7, hydrogen bonding may be interrupted by an excess of hydroxide ions.
이상의 제조방법에 의해 제공되는 플라보노이드/고분자 복합구형체는 다공성 고분자 입자의 표면에 다량의 플라보노이드가 분자 단위로 침착, 고정된 미세 분말상의 구형체로서, 화장료 기제에 용이하게 분산 배합됨으로써 다양한 제형화가 가능하며, 피부 도포시 펴발림성이 향상되고 거친 입자감이 없어 우수한 사용감을 제공할 수 있다. 뿐만 아니라 외부 자극에 의한 분자 변성이 최소화되어 제형내 역가 보존이 가능하다. 따라서, 본 발명에 의하면 플라보노이드의 생리활성 효과를 화장료 제형으로 제공할 수 있다.The flavonoid / polymer composite sphere provided by the above manufacturing method is a fine powdery spherical body in which a large amount of flavonoids are deposited and fixed on the surface of porous polymer particles in a molecular unit, and various formulations are possible by being easily dispersed and blended in a cosmetic base. In addition, the spreadability is improved when the skin is applied and there is no coarse grain to provide an excellent feeling of use. In addition, molecular denaturation due to external stimuli is minimized, which allows preservation of titers in the formulation. Therefore, according to the present invention can provide the physiological activity effect of the flavonoids in the cosmetic formulation.
본 발명의 플라보노이드/고분자 복합구형체를 화장료 조성물에 배합하는 경우, 그 제형에 있어서 특별히 한정되지는 않으나, 수분에 의한 분자 변성을 배제할 수 있는 무수계 제형이 보다 더 바람직하다. 구체적으로, 유연화장수, 영양화장수, 마사지크림, 영양크림, 젤, 팩, 에센스, 립스틱, 메이컵 베이스, 파운데이션, 로션, 연고, 크림, 패취 및 분무제 등을 들 수 있다.When the flavonoid / polymer composite spherical body of the present invention is blended into the cosmetic composition, it is not particularly limited in the formulation, but anhydrous formulation which can exclude molecular denaturation by moisture is more preferable. Specifically, flexible cosmetics, nourishing cosmetics, massage creams, nutrition creams, gels, packs, essences, lipsticks, makeup bases, foundations, lotions, ointments, creams, patches and sprays.
이하, 실시예 및 비교예, 실험예를 통하여 본 발명을 보다 더 구체적으로 설명한다. 그러나 이들 실시예는 본 발명을 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당 업계에서 통상의 지식을 가진 자에게 있어서 자명한 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples, Comparative Examples, and Experimental Examples. However, these examples are intended to illustrate the present invention, it is obvious to those skilled in the art that the scope of the present invention is not limited to these examples.
<실시예 1> 다공성 고분자 입자의 제조 및 EGCg 침착Example 1 Preparation of Porous Polymer Particles and EGCg Deposition
다공성 고분자 입자는 하기의 과정으로 제조하였다. 반응기에 메틸메타크릴레이트/에틸렌 글리콜 디메타크릴레이트(가교제)/톨루엔을 중량 대비 18/42/40의 비율로 혼합하여 100g을 제조하였다. 상기의 용액에 개시제인 2,2-아조비스(2,4-디메틸 발레로니트릴)을 단량체에 대해 1중량%로 도입한 다음 실온에서 교반하여 완전히 용해시켰다. 이어서, 제조된 용액을 1%의 폴리비닐알콜(평균 검화도 89%)이 녹아 있는 수용액에 넣고 기계식 호모게나이저를 이용하여 6,000rpm에서 5분간 유화시켰다. 이 때, 메틸메타크릴레이트/가교제/개시제/톨루엔 용액은 수상에서 15중량%의 농도를 갖는다. 이어서, 반응기의 온도를 70℃로 높이고 10시간 동안 중합한 후, 여과지를 통하여 제조된 다공성 고분자 입자를 여과하여 회수하였다. 메탄올을 이용하여 미 반응물과 분산 안정제를 반복하여 세척한 후 진공 오븐에서 24시간 건조시켜 분말 형태로 얻었다.Porous polymer particles were prepared by the following procedure. 100 g was prepared by mixing methyl methacrylate / ethylene glycol dimethacrylate (crosslinking agent) / toluene in a ratio of 18/42/40 to weight in the reactor. 2,2-Azobis (2,4-dimethyl valeronitrile), which is an initiator, was introduced into the solution at 1% by weight based on the monomer, followed by stirring at room temperature to completely dissolve it. Subsequently, the prepared solution was placed in an aqueous solution in which 1% of polyvinyl alcohol (average degree of saponification of 89%) was dissolved and emulsified at 6,000 rpm for 5 minutes using a mechanical homogenizer. At this time, the methyl methacrylate / crosslinker / initiator / toluene solution has a concentration of 15% by weight in the water phase. Subsequently, after raising the temperature of the reactor to 70 ° C. and polymerizing for 10 hours, the porous polymer particles prepared through the filter paper were collected by filtration. The unreacted material and the dispersion stabilizer were repeatedly washed with methanol, and then dried in a vacuum oven for 24 hours to obtain a powder.
이렇게 하여 얻은 다공성 고분자 입자를 물에 전체 중량 대비 20중량%로 분산시켰다. 또한, EGCg를 전체 중량 대비 3중량%로 용해시켜 수용액을 제조한 후에 다공성 고분자 입자가 분산된 분산액에 서서히 혼합시켰다. 30분 추가 교반 후 여과지를 통하여 EGCg가 침착된 다공성 고분자 입자를 여과한 후 진공 오븐에서 24시간 건조시켜 분말 형태로 얻었다.The porous polymer particles thus obtained were dispersed in water at 20% by weight relative to the total weight. In addition, EGCg was dissolved in 3% by weight of the total weight to prepare an aqueous solution, and then slowly mixed into the dispersion in which the porous polymer particles were dispersed. After 30 minutes of further stirring, the porous polymer particles having EGCg deposited thereon were filtered through a filter paper and then dried in a vacuum oven for 24 hours to obtain a powder.
<실시예 2> 니트릴기를 갖는 다공성 고분자 입자의 제조 및 EGCg 침착Example 2 Preparation of Porous Polymer Particles Having Nitrile Group and EGCg Deposition
메틸메타크릴레이트/아세토니트릴/에틸렌 글리콜 디메타크릴레이트 /톨루엔을 중량 대비 12/6/42/40의 비율로 혼합하여 사용하는 것을 제외하고는 실시예 1과 동일한 과정으로, 표면에 니트릴기를 갖는 다공성 고분자 입자를 제조하였다. EGCg 침착 과정은 실시예 1과 동일하게 진행하였다.Except for using methyl methacrylate / acetonitrile / ethylene glycol dimethacrylate / toluene in a ratio of 12/6/42/40 to the weight by the same procedure as in Example 1, having a nitrile group on the surface Porous polymer particles were prepared. EGCg deposition process was the same as in Example 1.
<실시예 3> 히드록시기를 갖는 다공성 고분자 입자의 제조 및 EGCg 침착Example 3 Preparation of Porous Polymer Particles Having Hydroxy Group and EGCg Deposition
메틸메타크릴레이트/비닐아세테이트/에틸렌 글리콜 디메타크릴레이트 /톨루엔을 중량 대비 12/6/42/40의 비율로 혼합하여 사용하는 것을 제외하고는 실시예 1과 동일한 과정으로 중합 반응을 진행하였다. 중합 종료 후 반응물에 0.8중량%의 수산화나트륨을 첨가하여 10시간 동안 실온에서 아세테이트를 검화시킴으로써 표면에 히드록시기를 갖는 다공성 고분자 입자를 제조하였다. EGCg 침착 과정은 실시예 1과 동일하게 진행하였다The polymerization reaction was carried out in the same manner as in Example 1 except that methyl methacrylate / vinylacetate / ethylene glycol dimethacrylate / toluene was mixed at a ratio of 12/6/42/40 to weight. After the completion of the polymerization, 0.8 wt% sodium hydroxide was added to the reaction to saponify acetate at room temperature for 10 hours to prepare porous polymer particles having a hydroxyl group on the surface. EGCg deposition process was the same as in Example 1
<실시예 4> 카르복실기를 갖는 다공성 고분자 입자의 제조 및 EGCg 침착Example 4 Preparation of Porous Polymer Particles Having a Carboxyl Group and EGCg Deposition
메틸메타크릴레이트/메타크릴산/에틸렌 글리콜 디메타크릴레이트 /톨루엔을 중량 대비 12/6/42/40의 비율로 혼합하여 사용하는 것을 제외하고는 실시예 1과 동일한 과정으로, 표면에 카르복실기를 갖는 다공성 고분자 입자를 제조하였다. EGCg 침착 과정은 실시예 1과 동일하게 진행하였다.The same procedure as in Example 1 was carried out except that methyl methacrylate / methacrylic acid / ethylene glycol dimethacrylate / toluene was mixed at a ratio of 12/6/42/40 to weight, and a carboxyl group was formed on the surface. The porous polymer particles having were prepared. EGCg deposition process was the same as in Example 1.
<실험예 1> 실시예 1~4에서 제조된 EGCg/고분자 복합구형체의 특성 분석Experimental Example 1 Characterization of the EGCg / Polymer Composite Spheres Prepared in Examples 1 to 4
실시예 1~4에서 제조된 EGCg/고분자 복합구형체를 BET (Brunauer, Emmett and Teller)와 액상크로마토그래피를 이용하여 분석하였다. 그 결과를 다음 표 1에 정리하였다.The EGCg / polymer composite spheres prepared in Examples 1 to 4 were analyzed using BET (Brunauer, Emmett and Teller) and liquid chromatography. The results are summarized in Table 1 below.
상기 표 1에서 보는 바와 같이, 실시예 1~4에서 제조된 다공성 고분자 입자는, 표면관능기의 존재 유무에 상관없이, 200㎡/g 이상의 넓은 표면적과 10~20㎚ 크기의 작은 포어를 갖고 있음을 알 수 있다. 그러나, EGCg 도입량은 다공성 특성보다 상호작용력을 갖는 관능기의 존재 유무에 크기 의존함을 알 수 있다. 특히, EGCg에 존재하는 히드록시기와 수소결합을 할 수 있는 니트릴기와 히드록시기를 표면에 갖는 다공성 입자가 EGCg 침착에 보다 효과적임을 확인할 수 있다. 전체적으로 EGCg 침착 효율은 75% 전후에서 조절 가능하다.As shown in Table 1, the porous polymer particles prepared in Examples 1 to 4 have a large surface area of 200 m 2 / g or more and small pores of 10-20 nm size, regardless of the presence or absence of surface functional groups. Able to know. However, it can be seen that the amount of EGCg introduced depends on the presence or absence of functional groups having interaction force rather than porosity. In particular, it can be seen that the porous particles having a nitrile group and a hydroxyl group capable of hydrogen bonding with the hydroxy group present in the EGCg are more effective for EGCg deposition. Overall, EGCg deposition efficiency is adjustable around 75%.
<실험예 2> 실시예 1~4에서 제조된 EGCg/고분자 복합구형체의 구조 분석Experimental Example 2 Structural Analysis of the EGCg / Polymer Composite Spheres Prepared in Examples 1 to 4
실시예 1~4에서 제조된 다공성 고분자 입자와 EGCg가 표면 침착된 복합구형체의 분말 형태를 주사전자현미경으로 확인하여 그 결과를 도 1~3에 나타내었다. 실시예 1~4에서 제조된 다공성 고분자 입자는 모두 동일한 입자형태를 갖고 있다. 그 중 실시예 2에서 제조한 니트릴기를 갖는 다공성 고분자 입자를 도 1에 나타내었다. 제조된 입자는 현탁중합법을 적용하였기 때문에 전체적으로는 다분산성을 갖고 있지만 5~10㎛의 평균 입자 크기를 나타내고 있고 모두 표면에 다공성을 지니고 있다. 도 2에서의 표면확대된 주사전자현미경 사진에서 표면 다공성을 직접적으로 확인할 수 있다. 또한, 도 3에 EGCg가 침착된 다공성 고분자 입자의 전자주사현미경 사진을 나타내었다. 제조된 다공성 고분자 입자에 EGCg를 침착하더라도 외관상 형태의 변화는 관찰되지 않았다.The powder form of the porous polymer particles prepared in Examples 1 to 4 and the composite spherical body on which the EGCg was surface deposited was confirmed by scanning electron microscope, and the results are shown in FIGS. 1 to 3. The porous polymer particles prepared in Examples 1 to 4 all have the same particle shape. Among them, porous polymer particles having a nitrile group prepared in Example 2 are shown in FIG. 1. The prepared particles have a polydispersity as a whole due to the suspension polymerization method, but have an average particle size of 5 to 10 μm and all have porosity on the surface. Surface porosity can be directly confirmed from the surface magnified scanning electron micrograph in FIG. In addition, FIG. 3 shows an electron scanning micrograph of EGCg-deposited porous polymer particles. Even when EGCg was deposited on the prepared porous polymer particles, no change in appearance was observed.
<실험예 3> 실시예 1~4에서 제조된 EGCg/고분자 복합구형체의 저장 안정성Experimental Example 3 Storage Stability of EGCg / Polymer Composite Spheres Prepared in Examples 1 to 4
실시예 1~4에서 제조된 EGCg/고분자 복합구형체의 저장 안정성은 6개월간 실온과 45℃에서 보관하면서 액상크로마토그래피를 이용하여 관찰하였다. 보관은 수분이 차단된 일반 폴리에틸렌 플라스틱 튜브를 이용하였다. 그 결과 본 발명의 EGCg/고분자 복합구형체는 분말상에서 안정도가 단지 2% 이내에서 감소함을 확인하였다. 따라서, 분말상에서 저장이 가능함을 제시한다.The storage stability of the EGCg / polymer composite spheres prepared in Examples 1 to 4 was observed using liquid chromatography while storing at room temperature and 45 ℃ for 6 months. Storage was by using a normal polyethylene plastic tube blocked water. As a result, it was confirmed that the stability of the EGCg / polymer composite sphere of the present invention in the powder phase only within 2%. Thus, it is suggested that storage is possible in powder form.
<실험예 4> 수계 화장료 제형에서의 안정도Experimental Example 4 Stability in Water-Based Cosmetic Formulations
실시예 1~4에서 제조된 EGCg/고분자 복합구형체의 수계 화장료 제형에서의 안정성을 확인하기 위해, 다음 표 2의 조성으로 수계 제형을 제조하였다. 또한 안정성을 비교하기 위해 다공성 입자에 침착시키지 않은 EGCg를 첨가하여 제조하였다. 제형 내 EGCg 함량은 0.1중량%로 조절하였다.In order to confirm the stability in the aqueous cosmetic formulation of the EGCg / polymer composite spheres prepared in Examples 1 to 4, an aqueous formulation was prepared with the composition of Table 2 below. It was also prepared by adding EGCg not deposited on the porous particles to compare the stability. The EGCg content in the formulation was adjusted to 0.1% by weight.
상기 제조된 시료를 실온 및 40℃ 오븐에 각각 보관하여 일정시간이 지난 후 액상크로마토그래피를 이용하여 잔여 EGCg의 함량을 측정하였다. 이를 초기 함량과 비교하여 그 함량 유지율을 백분율로 표 3에 나타내었다.The prepared samples were stored in an oven at room temperature and 40 ° C., respectively, and after a certain period of time, the residual EGCg content was measured using liquid chromatography. Compared with the initial content it is shown in Table 3 as a percentage of the content retention.
본 실험예에서 관찰한 모든 시료는 단시간 내에 모두 안정도를 잃어버리는 결과를 나타내었다. 다공성 입자에 침착시킨 경우 순수한 EGCg보다는 안정도 유지능이 있으나, 궁극적인 안정화에는 도달하지 못 하였다. 이상의 결과는 물이 EGCg 변성을 야기시키는 결정적인 요인임을 다시 한번 더 증명하고 있다. 따라서, EGCg 안정화를 위해서는 무수계가 적절함을 알 수 있다. 그렇지만, 종래 안정성 때문에 수상에서는 사용이 불가능하다고 여겨졌던 EGCg의 안정도를, 본 발명에서는 상기와 같이 향상시켰으며, 이는 EGCg를 수상에서도 사용할 수 있는 가능성을 제시한다.특히 화장료의 제조과정이나 사용과정 중(사용직전 혼합하여 사용하는 제형 등)에 있어서, 상기와 같은 안정도 향상은 많은 응용가능성을 제시한다.All the samples observed in this experimental example showed a result of losing stability in a short time. When deposited on porous particles, stability was more stable than pure EGCg, but ultimate stability was not reached. The above results demonstrate once again that water is the decisive factor in causing EGCg denaturation. Therefore, it can be seen that anhydrous system is suitable for EGCg stabilization. However, the stability of EGCg, which was previously considered impossible to use in an aqueous phase due to its stability, is improved as described above in the present invention, which suggests the possibility of using EGCg in an aqueous phase. In (formulations used by mixing just before use, etc.), such stability improvement suggests many applications.
<실험예 5> 무수계 화장료 제형에서의 안정도Experimental Example 5 Stability in Anhydrous Cosmetic Formulation
실시예 1~4에서 제조된 EGCg/고분자 복합구형체의 무수계 화장료 제형에서의 안정성을 확인하기 위해, 다음 표 4의 조성으로 무수계 제형을 제조하였다. 또한 안정성을 비교하기 위해 다공성 입자에 침착시키지 않은 EGCg를 첨가하여 제조하였다. 제형 내 EGCg 함량은 0.1중량%로 조절하였다.In order to confirm the stability in the anhydrous cosmetic formulation of the EGCg / polymer composite spheres prepared in Examples 1 to 4, anhydrous formulations were prepared with the composition of Table 4 below. It was also prepared by adding EGCg not deposited on the porous particles to compare the stability. The EGCg content in the formulation was adjusted to 0.1% by weight.
상기 제조된 시료를 실온 및 40℃ 오븐에 각각 보관하여 일정시간이 지난 후 액상크로마토그래피를 이용하여 잔여 EGCg의 함량을 측정하였다. 이를 초기 함량과 비교하여 그 함량 유지율을 백분율로 표 5에 나타내었다.The prepared samples were stored in an oven at room temperature and 40 ° C., respectively, and after a certain period of time, the residual EGCg content was measured using liquid chromatography. Compared with the initial content it is shown in Table 5 as a percentage of the content retention.
또한, 상기 제조된 시료를 실온에서 공기 중에 일광 노출된 상태로 각각 보관하여 3개월이 지난 후 외관 색상 변화와 액상크로마토그래피를 이용하여 잔여 EGCg의 함량을 측정하여 초기 함량과 비교함으로써 공기중의 수분, 산소 및 빛에 대한 안정성을 비교하였다. 그 결과를 표 6에 나타내었다.In addition, the prepared samples were stored in the air at room temperature exposed to sunlight, respectively, and after three months, the content of residual EGCg was measured using the change in appearance color and liquid chromatography, and compared with the initial content. , Stability against oxygen and light was compared. The results are shown in Table 6.
상기한 표 5 및 표 6에서 보는 바와 같이, 고분자 입자에 침착된 EGCg는 3개월 경과 후에도 초기의 연한 분홍색을 그대로 유지하고 있으며 95% 이상의 우수한 안정도를 나타내었다. 이는 다공성 입자의 넓은 표면에 EGCg가 분자 단위로 침착되어 고정됨으로써, 열이나 공기중의 수분, 산소, 빛 등에 대해 분자 구조의 변성 없이 EGCg 그대로 유지하고 있어 제형 내에서 그의 활성 역가를 보존할 수 있음을 시사한다.As shown in Table 5 and Table 6, the EGCg deposited on the polymer particles retained the initial pale pink after three months and showed excellent stability of 95% or more. This is because the EGCg is deposited on a large surface of the porous particles in a molecular unit and is fixed, so that the EGCg is maintained as it is without modification of molecular structure against heat, moisture, oxygen, and light in the air, thereby preserving its active titer in the formulation. Suggests.
반면에, 비교제형예 2의 경우 열 안정도는 우수하나, 공기중의 수분, 산소, 빛 등에 의해 EGCg의 분자 변성이 일어나 외관의 색상이 붉은 갈색으로 변색되고(갈변현상), 초기의 함량 역시 감소하여, 제형 내에서 그의 활성 역가를 보존할 수 없음을 알 수 있다.On the other hand, in Comparative Example 2, the thermal stability is excellent, but the molecular color of EGCg is changed due to moisture, oxygen, light, etc. in the air, so that the appearance color becomes reddish brown (browning phenomenon), and the initial content is also reduced. It can be seen that it is not possible to preserve its active titer in the formulation.
<실험예 6> 사용감 비교Experimental Example 6 Comparison
제형예 5와 비교제형예 2에 대해 관능검사를 통하여 사용감을 평가하였다. 관능검사는 피검자 30명을 대상으로 하기 표 7의 판정기준에 따라 실시하였으며, 판정치를 평균한 결과를 하기 표 8에 나타내었다. For Formulation Example 5 and Comparative Formulation Example 2, the usability was evaluated through sensory tests. The sensory test was performed on 30 subjects according to the criterion of Table 7 below, and the results of averaging the results are shown in Table 8 below.
상기한 표 8로부터, 본 발명의 EGCg/고분자 복합 구형체를 함유한 제형의 경우 사용감이 우수함을 확인할 수 있다. 이는 침상의 EGCg를 다공성 고분자 입자의 표면에 고정하여 구형화함으로써 피부 도포시 펴발림성을 향상시킬 수 있고 거친 입자감이 없어 우수한 사용감을 제공할 수 있음을 시사한다. 반면에, 침상의 EGCg 자체를 제형화한 비교제형예 2의 경우, 펴발림성이 나쁘고, 특히 거친 입자감 때문에 사용감이 나쁜 것으로 평가되었다.From Table 8 above, it can be confirmed that the formulation containing the EGCg / polymer composite sphere of the present invention is excellent in feeling. This suggests that spherical EGCg may be fixed on the surface of the porous polymer particles to be spherical to improve spreadability during application of the skin and provide excellent feeling without rough grain. On the other hand, in Comparative Formulation Example 2 in which the needle-like EGCg itself was formulated, the spreadability was poor, and in particular, the feeling was poor because of the coarse graininess.
이상에서 설명한 바와 같이, 본 발명에 제안하는 EGCg가 표면에 과량 침착된 다공성 고분자 구형복합체는 항산화능이 탁월한 EGCg를 함유시킬 수 있고 안정도를 유지하면서 제형에 도입할 수 있어, 향후 EGCg를 함유하는 다양한 화장료 개발이 가능할 것으로 기대된다. 게다가, 안정도가 극도로 낮고 물 또는 오일에 대하여 용해도가 낮은 플라보노이드류 또는 터페노이드류와 같은 다양한 항산화제에 대한 안정화 시스템 개발에 유용하게 이용할 수 있을 것으로 기대된다. As described above, the porous polymer spherical complex in which the EGCg proposed in the present invention is excessively deposited on the surface can contain EGCg having excellent antioxidant ability and can be introduced into the formulation while maintaining stability, and thus various cosmetics containing EGCg in the future. Development is expected to be possible. In addition, it is expected to be useful in developing a stabilization system for various antioxidants such as flavonoids or terpenoids having extremely low stability and low solubility in water or oil.
도 1은 다공성 고분자 입자의 주사전자현미경 사진이다.1 is a scanning electron micrograph of the porous polymer particles.
도 2는 도 1의 다공성 고분자 입자의 표면을 확대한 주사전자현미경 사진이다.FIG. 2 is an enlarged scanning electron micrograph of the surface of the porous polymer particle of FIG. 1.
도 3은 EGCg가 표면 침착된 다공성 고분자 복합구형체(이하, "EGCg/고분자 복합구형체")의 주사전자현미경 사진이다.FIG. 3 is a scanning electron micrograph of a porous polymer composite sphere (hereinafter, "EGCg / polymer composite sphere") on which EGCg is deposited.
Claims (15)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030081451A KR100581215B1 (en) | 2003-11-18 | 2003-11-18 | Flavonoids / Polymer composite spheres and preparation method thereof, and cosmetic composition containing the same |
PCT/KR2004/001304 WO2005049704A1 (en) | 2003-11-18 | 2004-06-01 | Flavonoid-deposited polymer composite particles and a process for preparation of the same, and cosmetic compositions containing the same |
CN2004800338968A CN1882645B (en) | 2003-11-18 | 2004-06-01 | Flavonoid-deposited polymer composite particles and a process for preparation of the same, and cosmetic compositions containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020030081451A KR100581215B1 (en) | 2003-11-18 | 2003-11-18 | Flavonoids / Polymer composite spheres and preparation method thereof, and cosmetic composition containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050047693A true KR20050047693A (en) | 2005-05-23 |
KR100581215B1 KR100581215B1 (en) | 2006-05-22 |
Family
ID=34617237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020030081451A KR100581215B1 (en) | 2003-11-18 | 2003-11-18 | Flavonoids / Polymer composite spheres and preparation method thereof, and cosmetic composition containing the same |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR100581215B1 (en) |
CN (1) | CN1882645B (en) |
WO (1) | WO2005049704A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100600470B1 (en) * | 2004-10-26 | 2006-07-13 | 주식회사 선진화학 | Method for preparing porous polymethyl methacrylate |
KR101230932B1 (en) * | 2006-12-07 | 2013-02-07 | (주)아모레퍼시픽 | Cosmetic composition containing macromolecular composite particles with flavon |
KR20210058440A (en) | 2019-11-14 | 2021-05-24 | (주)두와이즈켐 | Sustained antibacterial curable coating composition |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100008869A1 (en) * | 2006-07-21 | 2010-01-14 | Kao Corporation | Method for preventing coloration of catechins and dentifrice composition |
US10722436B2 (en) | 2015-08-10 | 2020-07-28 | Mary Kay Inc. | Topical compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5432638A (en) * | 1977-08-17 | 1979-03-10 | Asahi Denka Kogyo Kk | Cosmetic base composition |
FR2697159B1 (en) * | 1992-10-22 | 1995-01-13 | Oreal | Cosmetic or dermo-pharmaceutical composition containing in combination a lauroylmethionate of a basic amino acid and at least one polyphenol. |
FR2715582B1 (en) * | 1994-02-02 | 1996-03-15 | Centre Nat Rech Scient | Microcapsules with crosslinked flavonoid walls and compositions containing them. |
JP4040129B2 (en) * | 1996-05-27 | 2008-01-30 | 株式会社エルブ | Finely pulverized composite and external composition for blending into external composition |
DE19805572A1 (en) * | 1998-02-12 | 1999-08-19 | Beiersdorf Ag | New, stable intercalates of sensitive active agent, e.g. sunscreen, in nanoporous carrier useful as cosmetic and dermatological formulations and also in skin and hair treatment |
JP4197091B2 (en) * | 2000-12-27 | 2008-12-17 | 花王株式会社 | Cosmetics |
KR100449228B1 (en) * | 2002-03-19 | 2004-09-18 | 주식회사 태평양 | EGCG derivatives, Preparation method thereof and cosmetic composition containing thereof |
-
2003
- 2003-11-18 KR KR1020030081451A patent/KR100581215B1/en active IP Right Grant
-
2004
- 2004-06-01 WO PCT/KR2004/001304 patent/WO2005049704A1/en active Application Filing
- 2004-06-01 CN CN2004800338968A patent/CN1882645B/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100600470B1 (en) * | 2004-10-26 | 2006-07-13 | 주식회사 선진화학 | Method for preparing porous polymethyl methacrylate |
KR101230932B1 (en) * | 2006-12-07 | 2013-02-07 | (주)아모레퍼시픽 | Cosmetic composition containing macromolecular composite particles with flavon |
KR20210058440A (en) | 2019-11-14 | 2021-05-24 | (주)두와이즈켐 | Sustained antibacterial curable coating composition |
Also Published As
Publication number | Publication date |
---|---|
CN1882645B (en) | 2013-04-17 |
WO2005049704A1 (en) | 2005-06-02 |
CN1882645A (en) | 2006-12-20 |
KR100581215B1 (en) | 2006-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0277211B1 (en) | Polymeric carrier compositions and methods for their preparation and use | |
EP1937204B1 (en) | Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same | |
WO2005004832A1 (en) | Sustained release compositions and controlled delivery method | |
CN114073644B (en) | Cosmetic composition containing capsules | |
KR20150129859A (en) | Porous resin particle, method for producing same, dispersion, and application thereof | |
WO2014163310A1 (en) | Method for preparing macroporous polymethyl methacrylate | |
KR100581215B1 (en) | Flavonoids / Polymer composite spheres and preparation method thereof, and cosmetic composition containing the same | |
US20040161438A1 (en) | Cosmetic preparations comprising active ingredients in microcapsules | |
Nokhodchi et al. | The Effect of Formulation Type on the Release of Benzoyl Peroxide from Microsponges: Benzoyl peroxide release from microsponges | |
KR101262261B1 (en) | Polymer nanocapsules and the process for preparing the same, and the skin external composition containing the nanocapsules | |
KR100328972B1 (en) | Method for Producing Cosmetic or Skincare-pharmaceutical Composition Containing Nutritional Supplement and the Cosmetic or Skincare-pharmaceutical Composition Produced by the Above-method | |
KR100836032B1 (en) | L-ascorbic acid-containing multi-porous polymer microcapsules, preparation method thereof and cosmetic composition containing same | |
KR101272741B1 (en) | Cationic polymer nanocapsules for the stabilization of active ingredients and the process for preparing the same, and the cosmetic composition containing the nanocapsules | |
JP2022013828A (en) | Surface-treated inorganic particles, manufacturing method of the same, dispersion solution of the same, and cosmetic composition including the same | |
KR102163884B1 (en) | Spherical hydrogel particles using MPC and water-soluble crosslinking agent | |
KR101096374B1 (en) | Effective ingredient stabilization method using polyol / polymer microcapsules and cosmetic composition containing same | |
KR100825834B1 (en) | Method for producing oil-soluble active substance stabilized thermotropic liquid crystal microcapsules using liquid crystal array stabilization system (LAS) and cosmetic composition containing the same | |
KR102195983B1 (en) | Method for producing a cosmetic composition comprising silica ceramide composite | |
KR101193606B1 (en) | Cosmetic Composition for Enhancing Skin Penetration Containing pH Responsive Nano Particles and Biomimetic Surfactant | |
KR100488798B1 (en) | Water-in-oil-in-water multiple emulsions containing stabilized L-ascorbic acid and the process for preparing the same, and the cosmetic composition thereof | |
KR20110035459A (en) | Egcg/polyester resin complex, process for preparing the same and cosmetic composition comprising the same | |
TW202317065A (en) | Surface modified retinoid immersion porous silica | |
CA1310583C (en) | Polymeric carrier compositions and methods for their preparation and use | |
KR101400355B1 (en) | Composition having improved light stability of natural materials | |
KR20130071951A (en) | Microsphere containing water soluble active materials and fat soluble active materials by multiple emulsion, method for preparation the microsphere, and cosmetic composition comprising the microsphere |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20031118 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20050729 Patent event code: PE09021S01D |
|
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20060106 Patent event code: PE09021S02D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20060510 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20060511 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20060512 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20090414 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20100413 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20110413 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20120427 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130429 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20130429 Start annual number: 8 End annual number: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140418 Year of fee payment: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20140418 Start annual number: 9 End annual number: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150430 Year of fee payment: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20150430 Start annual number: 10 End annual number: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170329 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20170329 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 14 |
|
PR1001 | Payment of annual fee |
Payment date: 20190325 Start annual number: 14 End annual number: 14 |
|
PR1001 | Payment of annual fee |
Payment date: 20200325 Start annual number: 15 End annual number: 15 |
|
PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20220222 |